NCT02953652View on ClinicalTrials.gov

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

February 17, 2022

Study Completion Date

February 17, 2022

Conditions

Peripheral T-Cell Lymphoma (PTCL)

Interventions

DRUG

HBI-8000

Orally twice weekly

Trial Locations (23)

Unknown

Akita

Bunkyōku

Chūōku

Fukuoka

Isehara

Kagoshima

Kobe

Kōtoku

Kumamoto

Kyoto

Maebashi

Nagoya

Okayama

Ōmura

Sapporo

Sayama

Suita

Yamagata

Busan

Goyang-si

Incheon

Seongnam-si

Seoul

All Listed Sponsors

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

HUYABIO International, LLC.

INDUSTRY

NCT02953652 - Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Biotech Hunter | Biotech Hunter